Telix Investors Face Jan. 9 Deadline in Securities Suit Over Drug and Manufacturing Disclosures

The case stems from regulatory disclosures by the SEC followed by the FDA that preceded double‑digit Telix ADS declines.

Overview

Multiple plaintiff firms, including Hagens Berman, Rosen, Faruqi & Faruqi, Robbins, Levi & Korsinsky, and Howard G. Smith, are urging investors to seek lead‑plaintiff status by January 9, 2026.
The complaints allege Telix overstated progress on prostate cancer candidates TLX591 and TLX592 and misstated the quality and regulatory compliance of third‑party manufacturing partners.
On July 22, 2025, Telix disclosed an SEC subpoena seeking documents on its prostate therapeutics disclosures, after which its ADSs fell more than 13% over two trading sessions.
On August 28, 2025, Telix reported an FDA Complete Response Letter for TLX250‑CDx (Zircaix) citing CMC deficiencies and Form 483 observations at two third‑party sites, followed by a drop of more than 21% in ADSs over two sessions.
The alleged class period runs from February 21 to August 28, 2025, the case is in early stages in the Southern District of Indiana with no certified class, and several firms are also soliciting whistleblowers.